Single Practice Six-Year Experience Treating Food Allergy With Oral Immunotherapy
Poster Feb 21, 2015
DM Pence1, AR Hague1, RL Wasserman1,2, SK Silvers1,2, RW Sugerman1,2, M Herbert3
Rationale: Interest in FOIT in the practice setting continues to increase. We report a review of 241 FOIT treated patients who reached their target dose and 53 who did not.
Methods: Retrospective record review of all patients initiating FOIT from 6/10/08 to 6/30/14, approved by the North Texas IRB. Patients received increasing FOIT doses with target doses of (mg of protein) cashew 2000, egg 4545, milk 8000, peanut 2000, pecan 2190, wheat 8000.
Results: 82% of patients reached their target dose. 66% of patients who reached the target dose and 62% of those who did not had a history of systemic reaction to the allergenic food before FOIT treatment.
Median FOIT asIgE (kU/L) dropped at least 48% immediately after FOIT completion. The median decrease in asIgE (kU/L) from before FOIT to one month after reaching the target dose was 48% whole egg, 67% egg white, 72% milk, and 51% peanut. Patients who discontinued treatment had a higher pre-FOIT asIgE than those who reached target.
Patients who discontinued FOIT had more epinephrine treated reactions (ETR) during escalation (2.56 ETR/1000 doses given) than those who reached target (0.86/1000 doses given).
Conclusions: A history of anaphylaxis before starting FOIT does not help predict which patients will reach the target dose. Those with higher pre-FOIT asIgE may be less likely to reach the target dose. An increase in reactions during escalation may be a predictor of patients that are more likely to discontinue FOIT.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE